Alembic Pharmaceuticals Limited has submitted the Exchange a copy of Voting Results and Srutinizers report of Annual General Meeting held on August 05, 2025
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals held its 15th AGM on August 5, 2025 via video conferencing, where all 9 resolutions were passed with the required majority. Out of 93,696 total shareholders, 80 attended through VC and 88.83% of total shares (17.46 crore out of 19.66 crore) were voted. Key items approved include adoption of FY25 financial statements, declaration of dividend for FY 2024-25, re-appointment of Mr. Shaunak Amin as Director, appointment of Statutory and Secretarial Auditors, ratification of Cost Auditor remuneration, and commission for Non-Executive Directors. Mr. Chirayu Amin was appointed as Executive Chairman (93.87% in favor) and Mr. Pranav Amin was re-appointed as Managing Director (90.73% in favor). Notably, public institutional investors showed significant dissent on the Managing Director's re-appointment (only 52.71% in favor) and the Executive Chairman's appointment (only 68.74% in favor).
All key resolutions passed, including confirmation of dividend for shareholders and continuation of the existing leadership team. However, the visible dissent from institutional investors on executive director appointments (especially the MD re-appointment with 9.27% against votes) may signal some investor concern over management compensation or governance, though promoter support ensured smooth passage of all resolutions.